8-chloro-3-(trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyrazine | 140911-31-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 8-chloro-3-(trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyrazine
• CAS: 140911-31-5
• 化学式: C₆H₂ClF₃N₄
• 分子量: 222.557
• InChiKey: MTJVSFDBHKNNPB-UHFFFAOYSA-N

物化性质

• 密度：
  1.84±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  14
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  43.1
• 氢给体数：
  0
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  (3S,4R)-4-methylbenzyl 4-(aminomethyl)-3-fluoropiperidine-1-carboxylate hydrochloride 、 8-chloro-3-(trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyrazine 在 N,N-二异丙基乙胺 作用下， 以 正丁醇 为溶剂， 以68%的产率得到(3S,4R)-4-methylbenzyl 3-fluoro-4-(((3-(trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyrazin-8-yl)amino)methyl)piperidine-1-carboxylate
  参考文献：
  名称：

  [EN] BICYCLIC AZAHETEROCYCLIC COMPOUNDS AS NR2B NMDA RECEPTOR ANTAGONISTS
  [FR] COMPOSÉS AZAHÉTÉROCYCLIQUES BICYCLIQUES UTILISÉS COMME ANTAGONISTES DES RÉCEPTEURS NMDA NR2B

  摘要：

  公开号：

  WO2016100349A3
• 作为产物：
  描述：

  3-(trifluoromethyl)[1,2,4]triazolo[4,3-a]pyrazine 7-oxide 在 三氯氧磷 作用下， 反应 2.5h， 生成 8-chloro-3-(trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyrazine
  参考文献：
  名称：

  [EN] FUSED TRIAZOLE DERIVATIVES AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES
  [FR] DERIVES DE TRIAZOLE ACCOLES INHIBITEURS DE LA DIPEPTIDYL PEPTIDASE-IV UTILISES DANS LE TRAITEMENT OU LA PREVENTION DU DIABETE

  摘要：

  公开号：

  WO2006023750A3

文献信息

• SUBSTITUTED 7-AZABICYCLES AND THEIR USE AS OREXIN RECEPTOR MODULATORS
  申请人：COATE Heather R.

  公开号：US20160046640A1

  公开（公告）日：2016-02-18

  The present invention is directed to compounds of Formula I: wherein ring A is phenyl, naphihalenyl, pyridyl, quinolinyl, isoquinolinyl, imidazopyridyl, furanyi, tlisazolyl, isoxazolvl, pyrazolyl, imidazothiazolyi, benzimidazolyl, or indazolyi; R 1 is H, alky], aikoxy, hydroxyalkylene, OH, halo, phenyl, triazolyl, oxazolyl, isoxazofyl, pyridyl, pyrimidinyl, pyrazinyl, pyridazmyl, piperazinyl, pyrazolyl, oxadiazolvl, pyrrolidinyl, thiophenyi, morpholinyl, or dialkyiamino; R 2 is H, alkyl, aikoxy, hydroxyalkylene, or halo; Z is NH, N-alkyl, or O; R 5 is pyridyl, pyrimidinyl, pyrazinyl, pyridazmyl, qumazolinyi, quinoxalinyl, pyrazolyl, benzoxazolyl, imidazopyrazinyl, triazolopyrazinyl, optionally substituted with a one or two substituents independently selected from the group consisting of alkyl, aikoxy, or halo; and n is 0 or 1, Methods of making the compounds of Formula 1 are also described. The invention also relates to pharmaceutical compositions comprising compounds of Formula I. Methods of using the compounds of the invention are also within the scope of the invention.

  本发明涉及式I的化合物：其中环A为苯基、萘基、吡啶基、喹啉基、异喹啉基、咪唑吡啉基、呋喃基、噻唑基、异噁唑基、吡唑基、咪唑噻唑基、苯并咪唑基或吲哚基；R1为H、烷基、烷氧基、羟基烷基、OH、卤素、苯基、三唑基、噁唑基、异噁唑基、吡啶基、嘧啶基、吡嗪基、吡啶并嗪基、哌嗪基、吡唑基、噁二唑基、吡咯烷基、噻吩基、吗啉基或二烷氨基；R2为H、烷基、烷氧基、羟基烷基或卤素；Z为NH、N-烷基或O；R5为吡啶基、嘧啶基、吡嗪基、吡啶并嗪基、喹唑啉基、喹喹啉基、吡唑基、苯并噁唑基、咪唑吡嗪基、三唑咪唑基，可选地取代一个或两个独立选择自烷基、烷氧基或卤素的基团；n为0或1，还描述了制备式I化合物的方法。本发明还涉及包含式I化合物的药物组合物。本发明还涉及使用该化合物的方法。
• 含杂芳基取代哒嗪酮结构的三唑并吡嗪类化 合物的制备及应用
  申请人：江西科技师范大学

  公开号：CN110467616B

  公开（公告）日：2021-12-21

  本发明涉及通式Ⅰ所示的含杂芳基取代哒嗪酮结构的三唑并吡嗪类化合物及其药学上可接受的盐、水合物、溶剂化物和前药，其中取代基R1、R2、X、和Y具有在说明书中给出的含义。本发明还涉及通式Ⅰ的化合物具有强的抑制c‑Met激酶的作用，并且还涉及该类化合物及其药学上可接受的盐、水合物、溶剂化物或前药在制备治疗由于c‑Met、EGFR、Flt‑3激酶异常高表达所引起疾病的药物中的用途，特别是在制备治疗和/或预防癌症的药物中的用途。
• Fused Triazole Derivatives as Dipeptidyl Peptidase-IV Inhibitors for the Treatment or Prevention of Diabetes
  申请人：Weber E. Ann

  公开号：US20070208010A1

  公开（公告）日：2007-09-06

  The present invention is directed to novel fused triazole derivatives which are inhibitors of the dipeptidyl peptidase-IV enzyme (“DPP-IV inhibitors”) and which are useful in the treatment or prevention of diseases in which the dipeptidyl peptidase-IV enzyme is involved, such as diabetes and particularly type 2 diabetes. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which the dipeptidyl peptidase-IV enzyme is involved.

  本发明涉及新型融合的三唑衍生物，它们是二肽基肽酶-IV酶（“DPP-IV抑制剂”）的抑制剂，可用于治疗或预防二肽基肽酶-IV酶参与的疾病，如糖尿病，特别是2型糖尿病。本发明还涉及包含这些化合物的药物组合物以及这些化合物和组合物在预防或治疗二肽基肽酶-IV酶参与的疾病中的使用。
• Fused triazole derivatives as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes
  申请人：Merck & Co., Inc.

  公开号：US07625888B2

  公开（公告）日：2009-12-01

  The present invention is directed to novel fused triazole derivatives which are inhibitors of the dipeptidyl peptidase-IV enzyme (“DPP-IV inhibitors”) and which are useful in the treatment or prevention of diseases in which the dipeptidyl peptidase-IV enzyme is involved, such as diabetes and particularly type 2 diabetes. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which the dipeptidyl peptidase-IV enzyme is involved.

  本发明涉及新型融合三唑衍生物，它们是二肽基肽酶-IV酶（“DPP-IV抑制剂”）的抑制剂，并且在治疗或预防涉及二肽基肽酶-IV酶的疾病，如糖尿病和特别是2型糖尿病方面非常有用。本发明还涉及包含这些化合物的制药组合物以及在预防或治疗涉及二肽基肽酶-IV酶的这些疾病中使用这些化合物和组合物的用途。
• FUSED TRIAZOLE DERIVATIVES AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES
  申请人：Merck Sharp & Dohme Corp.

  公开号：EP1784188B1

  公开（公告）日：2010-07-14